On Wednesday, Wells Fargo (NYSE:WFC) upgraded Merit Medical Systems , Inc. (NASDAQ:MMSI) to Overweight from Equal Weight, with an increased price target of $120.00, up from the previous $103.00. The stock, currently trading near its 52-week high of $106.87, is considered overvalued according to InvestingPro Fair Value metrics.
The firm anticipates that the upcoming launch of Wrapsody in the first quarter of 2025 will serve as a significant catalyst for Merit Medical (TASE:PMCN)'s growth in the coming years. The price target adjustment is based on approximately 28 times the firm's estimated earnings per share (EPS) for 2026.
The upgrade comes after a period of sustained performance improvements by Merit Medical, reflected in its impressive 50.9% stock return over the past year. Since a challenging year in 2020, the company has reported 17 consecutive quarters of revenue surpassing expectations and 14 quarters of operating margin (OM) growth.
Additionally, Merit Medical has seen a steady gross margin (GM) increase to 51.1% year-to-date, which marks a 400 basis point improvement since the third quarter of 2020, while maintaining revenue growth of 8.12% over the last twelve months.
Merit Medical's financial achievements have not gone unnoticed. The company has not only met but exceeded its previous long-range plans (LRP) for revenue and operating margin. With a "GREAT" financial health score from InvestingPro, which analyzes over 100 financial metrics, the firm's analysis suggests that Merit Medical has multiple levers to potentially enhance its 2026 long-range performance goals further. InvestingPro subscribers have access to 16 additional ProTips and comprehensive financial analysis for Merit Medical.
The analyst from Wells Fargo highlighted Merit Medical's consistent execution across various segments of its business as a key factor in the decision to upgrade the stock. The company's ability to maintain a trajectory of growth and margin improvement was critical to the analyst's more favorable outlook.
The Wells Fargo analyst concluded that Merit Medical's performance since September 2020, when the firm had initially set an Equal Weight rating, has demonstrated the company's resilience and capacity for consistent execution. This track record of success has set the stage for the analyst's confidence in the company's future prospects, particularly with the anticipated launch of Wrapsody.
In other recent news, Merit Medical Systems Inc. announced strong third-quarter results, with total revenue reaching $339.8 million, marking a 7.8% increase from the previous year. This growth surpassed company expectations, with non-GAAP operating profit seeing a 19% rise and free cash flow reaching $38 million for the quarter, a year-over-year increase of 116%.
In addition to financial growth, the company also reported the acquisition of Cook Medical's lead management portfolio, a move expected to generate significant revenue in the future. Updated financial guidance includes a GAAP net revenue growth forecast of 6.9% to 7.6% for 2024, with a non-GAAP diluted EPS expected to range from $3.33 to $3.38.
Despite acknowledging possible supply chain challenges impacting Q4 2023, the company remains confident in the demand for its OEM products and the performance of its sales team. These recent developments reflect a company on a positive trajectory, with strategic acquisitions and promising product developments, including the WRAPSODY program, which is currently in preparations for FDA approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.